Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An 18-Month Open Label Extension Study (OLES) of the Safety and Efficacy of Recombinant Human Parathyroid Hormone, rhPTH(1-84), ALX1-11, in Women With Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001 (TOP Study)

NCT00172133 is registered in ClinicalTrials.gov with Shire as lead sponsor.

NCT NCT00172133
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00172133 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An 18-Month Open Label Extension Study (OLES) of the Safety and Efficacy of Recombinant Human Parathyroid Hormone, rhPTH(1-84), ALX1-11, in Women With Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001 (TOP Study)
Lead sponsor
Shire
Phase
Phase 3
Overall status
Completed
Start date
October 16, 2001
Completion date
April 13, 2005
Enrollment
1,683 (actual)
Sites
132

Conditions

As the registry lists them; a condition with its own page is linked.

osteoporosis